Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q2 2020 · 10-Q
Revenue—
Net Income-$6.50M-$6.50MN/M vs Q2 2019 EPS Diluted-$0.39-$0.39N/M vs Q2 2019 Operating Income-$6,500,000N/M Operating Cash Flowderived-$5,448,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,448,000— ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end